|Traded as||NYSE: Q|
|Industry||Contract Research Organization
Pharmaceutical Service Consulting
|Headquarters||Durham, North Carolina, USA|
|Key people||Dennis Gillings, Executive Chairman
Tom Pike CEO
; Paula Brown Stafford, President Clinical
|Products||Support services for pharmaceutical, biotech and medical companies and individuals|
|Revenue||US$ Approximately $3.8 billion (2013)|
|Employees||~ 30,000 (2014)|
Quintiles Transnational (NYSE: Q), is a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 30,000 employees conducting business in approximately 100 countries, Quintiles helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market.
Since its founding over 30 years ago, Quintiles has grown to become a leader in the development and commercialization of new pharmaceutical therapies. The company's Product Development segment is the world’s largest contract research organization, or CRO, as ranked by reported service revenues, and is focused primarily on Phase II-IV clinical trials and associated laboratory and analytical activities. Quintiles' Integrated Healthcare Services (IHS) segment includes one of the leading global commercial pharmaceutical sales and service organizations. Integrated Healthcare Services provides a broad array of services, including commercial services, such as providing contract pharmaceutical sales forces in key geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector, such as outcome-based and payer and provider services.
Quintiles has extensive scientific, medical and therapeutic expertise which enables it to add sophisticated statistical, process development and advanced technology applications into its clinical development services to meet the needs of the broader healthcare industry for appropriate endpoints, adaptive trials, drug therapy analysis, outcome and real-world research and evidence-based medicine. Moreover, Quintiles' flexible business solutions and commitment to customers’ objectives allow Quintiles to provide its customers with customized operational delivery models to meet their particular needs.
- 1974: Dennis Gillings signs first contract to provide statistical and data management consulting for pharmaceutical clients.
- 1982: Quintiles, Inc., is incorporated in North Carolina.
- 1990: Quintiles Pacific Inc. and Quintiles Ireland Ltd. established
- 1991: Quintiles GMBH established in Germany; Quintiles Laboratories Ltd. established in Atlanta, Georgia
- 1996: Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO
- 1997: Quintiles goes public, completing successful secondary stock offering.
- 1998: Quintiles is the first company in industry to break the $1 billion mark, when it reports net revenues of $1.19 billion.
- 1999: Company joins the S&P 500 Index.
- 2003: Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
- 2009: Quintiles opens new corporate headquarters in Durham, North Carolina
- 2010: Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
- 2011: Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York
- 2013: Quintiles files for an IPO on 15 February in order to go public again 
- 2013: Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q 
- "Money, Math and Medicine". Forbes Magazine. November 22, 2010. Retrieved April 14, 2011.
- "High-Flying Quintiles to Buy Innovex in $747.5 Million Deal". New York Times. October 8, 1996. Retrieved April 14, 2011.
- Wall Street Journal, May 9, 2013